Home » Market News » DirectorsTalk Highlights » Women 4 times more likely to develop Lupus after stillbirth
Immupharma Plc

Women 4 times more likely to develop Lupus after stillbirth

Women who have gone through the trauma of having a stillbirth are four times more likely to develop Lupus than women with an uncomplicated livebirth, according to a University of Manchester study.

The researchers found a link between stillbirth and connective tissue disorders though Lupus had by far the strongest association.

Connective tissue disorders are a group of disorders involving the tissue that supports organs and other parts of the body

They also showed that the first signs of Lupus – the presence of antibodies – could appear up to five years after stillbirth without symptoms

Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.